- NURTEC ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine
- NURTEC ODT 75 mg is now the only migraine medication approved to both treat acute migraine attacks and help prevent future migraine attacks
- In a pivotal Phase 3 clinical trial, NURTEC rapidly and effectively prevented migraine, reducing migraine days by 30% after just 1 week of every other day treatment; by 3 months of treatment, approximately half of patients experienced at least a 50% reduction in moderate-to-severe migraine days
- NURTEC ODT was previously approved for acute treatment in all eligible adult patients with migraine, and the new indication of preventive treatment in adult patients with less than 15 headaches days per month expands the potential preventive use of NURTEC ODT to cover approximately 95% of individuals with migraine
PR Newswire
NEW HAVEN, Conn., May 27, 2021
